External broker reports(aggregated public sources), Axis Direct

Axis Direct

External broker reports(aggregated public sources)

Axis Direct is the flagship brand under Axis Securities Limited, a subsidiary of Axis Bank in India. 

Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

Equity Bottom-Up

<p>High competition in injectables generic and increase in raw material prices may impact the company's growth and margins in the upcoming quarters. Furthermore, we believe valuations are rich and thus recommend a HOLD with a target price of Rs 4,000/share</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

High competition in injectables generic and increase in raw material prices may impact the company's growth and margins in the upcoming quarters. Furthermore, we believe valuations are rich and thus recommend a HOLD with a target price of Rs 4,000/shareContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Gland Pharma: Strong Growth in Injectable; Rich Valuations

<p>We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3% from CMP.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3% from CMP.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Gland Pharma: Charting New Frontiers Of Growth

<p>We expect Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market, and therefore recommend HOLD with a TP of Rs 4,100/share.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

We expect Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market, and therefore recommend HOLD with a TP of Rs 4,100/share.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Gland Pharma: Strong Product Portfolio in Injectibles

External broker reports(aggregated public sources), Motilal Oswal Financial Services Limited

Motilal Oswal

<p>GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification.</p><div class="content-highlight"><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></div>

GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up manufacturing of the COVID-19 vaccine. It is concurrently developing products/undertaking capex related to complex product as well as enhancing its geographical diversification.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Complex products/newer markets to fortify growth pace

India

Gland Pharma Limited manufactures and markets small volume parenteral solutions.The Company offers injectables, including vials, ampoules, pre-filled syringes, lyophilized vials, dry powders, infusions, and ophthalmic solutions, and other active pharmaceutical ingredients. Gland Pharma conducts its business worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Gland Pharma Ltd (GLAND IN)

Gland Pharma: Strong Growth in Injectable; Rich Valuations

High competition in injectables generic and increase in raw material prices may impact the company's growth and margins in the upcoming quarters....

Axis Direct

Gland Pharma: Charting New Frontiers Of Growth

We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3%...

Axis Direct

Gland Pharma: Charting New Frontiers Of Growth

We expect revenue and PAT CAGR of 18.2% and 19.7% respectively over FY21-FY24E and recommend a HOLD with TP of Rs 4,100, implying an upside of 3%...

Axis Direct

Gland Pharma: Strong Product Portfolio in Injectibles

We expect Gland Pharma is well placed to grab upcoming opportunities in the injectables space in the US market, and therefore recommend HOLD with a...

Axis Direct

Complex products/newer markets to fortify growth pace

GLAND's 1QFY22 performance was ahead of our expectation, led by robust revenue growth across all geographies. It is progressing well on scaling up...

Motilal Oswal

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)